Optimal Sampling Times in Bioequivalence Studies Using a Simulated Annealing Algorithm by Choi, Leena et al.
Johns Hopkins University, Dept. of Biostatistics Working Papers
9-17-2004
Optimal Sampling Times in Bioequivalence
Studies Using a Simulated Annealing Algorithm
Leena Choi
Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics, lchoi@jhsph.edu
Brian Caffo
Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics, bcaffo@jhsph.edu
Charles Rohde
Johns Hopkins Bloomberg School of Public Health, Department of Biostatistics, crohde@jhsph.edu
This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the
copyright holder.
Copyright © 2011 by the authors
Suggested Citation
Choi, Leena; Caffo, Brian; and Rohde, Charles, "Optimal Sampling Times in Bioequivalence Studies Using a Simulated Annealing
Algorithm " (September 2004). Johns Hopkins University, Dept. of Biostatistics Working Papers. Working Paper 59.
http://biostats.bepress.com/jhubiostat/paper59
Optimal Sampling Times in Bioequivalence Studies Using
a Simulated Annealing Algorithm
Leena Choi, Brian Caffo, and Charles Rohde∗
September 17, 2004
Abstract
In pharmacokinetic (PK) studies, blood samples are taken over time on subjects after
the administration of a drug to measure the time-course of the plasma drug concentrations.
In bioequivalence studies, the trapezoidal rule on the sampled time points is often used
to estimate the area under the plasma concentration-time curve, a quantity of principle
interest. This manuscript investigates the choice of sampling time points to estimate
the area under the curve. In particular, we explore the relative merits of several objective
functions, those functions which are minimized with respect to the sampling times to obtain
an optimal study design. We propose an objective function which overcomes some of the
deficits of existing choices. We also present a simulated annealing algorithm to perform
the minimization. The main benefits of the simulated annealing algorithm are the ease in
which it can handle constraints on the sampling schedules and its ability to accommodate
a variety of models and objective functions. The manuscript presents optimal sampling
times for some key examples of true underlying models.
1 Introduction
In pharmacokinetic (PK) studies, blood samples are taken over time on subjects after the admin-
istration of a drug to measure the time-course of the plasma drug concentrations. A variety of
PK parameters are then estimated using the observed drug concentration profile for each subject.
The area under the (plasma/serum/blood) concentration time-curve (called AUC) is an important
parameter, since it is known to be a measure of the amount of drug absorbed, a quantity of special
interest in bioavailability (BA) and bioequivalence (BE) studies. The bioavailability of a drug is
quantified using AUC, the maximum drug concentration (called Cmax) and the associated time
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2where maximum concentration is reached (called tmax). Bioequivalence studies are performed as
part of the process of getting approval for a new drug formulation or a generic drug. The goal
of BE studies is to ascertain whether or not the bioavailability of the new formulation and an
existing approved formulation are equivalent. Here, AUC is used as the primary metric with Cmax
and tmax as secondary metrics. Therefore, accurately estimating AUC is an important aspect of
the drug development and evaluation process. In this manuscript, we explore the choice of the
placement of sampling times to better estimate AUC in BE studies.
Westlake (1979) summarized the selction of sampling times in BE studies with:“no universal
rule is apparent and a pragmatic approach is usually taken”. After a single dose of administration,
a rule of thumb is that blood samples are drawn at several times during the absorption phase of
the drug, then several times near the peak and at relatively fewer times in the elimination phase.
Usually, 10-15 total sampling times are employed. For example, for a drug with a half-life of 4-5
hours, a typical sampling schedule might be: 0, .5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 15 and 24 hours
following administration (Westlake, 1979). A diagramatic example of the estimated AUC using
11 sampling times for a PK model with two sets of PK parameter is shown in Figure 1.
Before continuing to the specific problem of sampling time selection in BE studies, we empha-
size the distinction between our focus and related areas of choosing pharmacokinetic sampling
time points. For example, consider the distinction between choosing sampling times for popu-
lation and individual PK studies on human subjects. Specifically, population PK studies focus
on investigating the population characteristics of PK parameters using a modelling approach. In
these studies, it is common to use sparse sampling times within each subject. Thus, it is critical
to reduce the bias and variance in estimating the PK model parameters. In contrast, as the name
would suggest, individual PK studies focus on individual PK characteristics. Some examples of
individual PK studies include preclinical PK studies, BA and BE studies. Unlike population PK
studies, individual PK studies employ many sampling times for moderate or small number of sub-
jects. In preclinical PK studies, pharmacologists are often interested in estimating individual PK
model parameters using the PK modelling approach. In BA and BE studies, however, nonpara-
metric estimation of AUC is the principal goal. It follows then, that methodologies for choosing
sampling time points are likely not the same in these areas. Furthermore, it should be noted that
the design of toxicokinetics/pharmacokinetics studies on animal subjects would also be different
still from any of the designs of PK studies on human subjects if “destructive sampling” is used.
That is, replicates of animals may be assigned at each time point, but sampled only once often
after sacrificing them. A review methodology for study design in toxicokinetics/pharmacokinetics
can be found in Beatty and Piegorsch (1997).
Here we review some of the related research on sampling time selection in PK studies. For the
design of population PK studies, the performance of several design strategies was evaluated using
simulation (Al-Banna et al., 1990). Wang and Endrenyi (1992) proposed a simulation approach
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3which they claim is more efficient than standard simulation approaches. Recently, several authors
have explored analytic solutions (Mentre´ et al., 1997; Tod et al., 1998; Retout et al., 2001).
These solutions are usually based on some variant of D-optimality (introduced in Box and Lucas,
1959) where a design is said to be D-optimal if the resulting estimate minimizes the determinant
of the inverse of the Fisher information matrix.
With regard to individual PK studies, several approaches have been proposed to find optimal
sampling time points. Atkinson et al. (1993) proposed an optimization method using a D-
optimality criteria for BA parameters such as AUC, Cmax and tmax. Katz and D’Argenio (1983)
proposed an algorithm which used the mean squared error (MSE) of the AUC estimate as an
objective function for finding optimal sampling times. Here, an objective function is a summary
function of the underlying true concentration time-curve and sampling times which is minimized
with respect to the sampling times to select an optimal placement of time points. Katz and
D’Argenio (1983) used quasi-Newton methods implemented in FORTRAN to minimize their
objective function. Wang (2001) used MSE for estimating the concentration time-curve using
linear interpolation instead of MSE of the AUC estimate. Kong and Gonin (2000) also based their
objective function on the error in linear interpolation, however using the squared bias as a summary
rather than MSE. They also accounted for between-subject (population level) heterogeneity by
numerically integrating their objective function over an assumed random effect distribution. Their
solution was implemented using a sequential quadratic programming algorithm.
Simulated annealing (SA) has been used sparingly in this area with some notable exceptions.
For example, Jones and Wang (1999) applied a simulated annealing algorithm to find starting
values, which are then used within a more locally efficient algorithm under a D-optimality criterion.
Duffull et al. (2002) used a simulated annealing algorithm for finding sampling time points in
population PK setting, also using a D-optimality criterion. Furthermore, they critically compared
simulated annealing with several other optimization algorithms.
In this manuscript we suggest a new objective function as well as a simulated annealing
algorithm to perform the minimization for choosing sampling time points to estimate AUC in
BE studies. The proposed objective function is conceptually based on using the squared bias in
estimating AUC. We note that a correction is necessary since the use of the direct estimate of
bias in optimization algorithms often results in convergence to sampling time points with little
face validity. To avoid this defect, we propose a simple correction that divides up the time
space. As a result of this correction, our objective function finds optimal sampling time points
taking into account not only the error in AUC estimate, but also the error in linear interpolation.
As in Kong and Gonin (2000) we employ both single subject and population averaged versions
of this objective function. We use Monte Carlo integration within our optimization algorithm
to simplify calculations. Finally, we propose a simulated annealing algorithm to perform the
optimization. Our choice of using simulated annealing was largely dominated by SA’s ability to
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4handle constraints on the sampling schedules and its ability to accommodate a variety of models
and objective functions.
The remainder of the paper is outlined as follows. In Section 2 we set up the problem and
notation while in Section 3 we review objective functions and propose a refinement of using the
squared bias of AUC estimate. Section 4 describes the proposed simulated annealing algorithm.
In Section 5, we compare the estimated sampling times using our proposed method with those
from other methods and also show potential problems depending on the models. A summary and
discussion follows in Section 6.
2 Estimating AUC
To better conceptualize estimating the AUC, we define a general PK model. Let f(t;β) denote
the underlying blood concentration for a subject at time t after the administration of a drug for
parameters β. Suppose that a given subject is sampled at time points tj for j = 0, . . . ,m + 1.
We assume that the responses, yj, for this subject satisfy
yj = f(tj;β) + ej, e | β ∼ {0,R(β;λ, σ)} β ∼ {µ,D(ξ)},
where the e is a vector comprised of the ej and the notation “∼ {a, b}” is short-hand for
“distributed with mean a and covariance b”. Here β is a vector of subject-specific PK parameters,
R(β;λ, σ) represents the within-subject covariance matrix for e andD(ξ) is the between-subject
covariance matrix for β. We assume that R(β;λ, σ) is a diagonal matrix with entries σ2j ≡
λ1 + σ
2f(tj;β)
λ2 where λi > 0.
The primary parameter of interest is the area under the concentration time-curve for a par-
ticular subject,
A∞t0 =
∫ ∞
0
f(t;β)dt.
Note that we are ommiting the dependence of A∞t0 on β and recall that this model refers to
a specific subject. Of course, in practice data is collected on several subjects where the above
model holds assuming conditional independence given the seperate β for each individual while
the parameters λ, σ, µ and ξ would be held fixed across subjects.
2.1 Approximation of AUC
There are two major approaches for estimating the AUC in PK studies: model based and non-
parametric. Model based estimation involves specifying a PK model for the observed data. A
common choice is to assume a compartmental model for f(t,β), Gaussian errors, a diagonal ma-
trix for R(β;λ, σ), and a Gaussian random effect distribution. In model based estimation, one
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5first estimates subject-specific PK parameters (using empirical Bayes methods, for example), then
integrates a plug-in estimate of the concentration time-curve. We point the reader to Davidian
and Giltinan (1995) for more information on PK model based approaches.
To avoid the problems of model misspecification, nonparametric approaches are more com-
monly used to estimate AUC in individual PK studies than parametric PK modelling approaches,
and nonparametric approaches are also the recommended method by the FDA. In what follows, we
investigate the optimal selection of sampling time points using the “trapezoidal rule” to estimate
AUC.
The trapezoidal rule is a numerical quadrature rule that is the most common nonparametric
estimate of the area under the drug concentration-time curve. This choice is well founded because
the trapezoidal rule has been shown to yield a good approximation to AUC when f(t;β) is
decreasing exponentially (Piegorsch and Bailer, 1989; Schempp, 1981), which is the case when
the true concentration time-curve follows one of the basic compartmental PK models. Bailer and
Piegorsch (1990) compared several quadrature methods for approximating AUC using MSE as
an objective function. They found that the trapezoidal rule had a relatively smaller variance. It
is worth noting that Bailer and Piegorsch (1990) showed the variance dominates in MSE criteria
unless the measurement error is very small.
Given the total number of sampling time points, the accuracy of the trapezoidal approximation
of the AUC depends on the placement of the time points. We denote the AUC between time t0
to tm+1 for a subject as
A
tm+1
t0 ≡
∫ tm+1
t0
f(t;β)dt.
The trapezoidal approximation to A
tm+1
t0 is
Aˆ
tm+1
t0 =
m+1∑
j=1
Aˆ
tj
tj−1 =
1
2
m+1∑
j=1
(yj + yj−1) (tj − tj−1) .
The trapezoidal approximation defines the integral only between the first and last sampling
time points, t0 and tm+1. In most PK studies, these times are fixed prior to the study with t0
being at the before administration of the drug and tm+1 being late enough to ensure the accuracy
of the approximation; usually, tm+1 is taken to be greater than 3 terminal half-lifes. The AUC
after the last sampling time point is typically approximated by Aˆ∞tm+1 = ym+1/k where k is the
subject specific elimination rate constant. The elimination rate constant can be either estimated
using a PK modelling approach or estimated using the last three sampling points of the current
data. Then we define
Aˆ∞t0 = Aˆ
tm+1
t0 + Aˆ
∞
tm+1
.
Conventional wisdom suggests that to otain an accurate estimates of AUC, Aˆ∞tm+1/Aˆ
∞
t0
should
be less than 3% for all subjects. However, it should be noted that the last sampling time cannot
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6always be chosen to satisfy this criteria as it is often fixed to 24 hours in BE studies, since it
is difficult to keep subjects beyond that time (Kong and Gonin, 2000). In our current study,
we focus only on accurately approximating the AUC up to the last sampling point under the
constraint that t0 and tm+1 are fixed.
2.2 Approximation of the underlying function
Another way to visualize the trapezoidal rule approximation of AUC comes from approximat-
ing the underlying function using linear interpolation (connecting adjacent points). That is, the
trapezoidal rule is the integral of the estimate of the concentration time-curve obtained by in-
terpolation. This interpretation is useful, as it suggests that objective functions for assessing the
error in AUC can be based on the error of the linear interpolation approximation.
The linear interpolated function fˆj(t) from tj−1 to tj can be expressed as:
fˆj(t) = aj + bjt, for tj−1 ≤ t ≤ tj, (1)
where
aj = −yjtj−1 − yj−1tj
tj − tj−1 , (2)
bj =
yj − yj−1
ti − tj−1 , (3)
and the integration of fˆj(t) over time interval results in:
Aˆ
tm+1
t0 =
m+1∑
j=1
Aˆ
tj
tj−1 =
m+1∑
j=1
∫ tj
tj−1
fˆj(t)dt.
3 The Objective Functions
Assuming that the true concentration-time curve f(t;β) is known and t0 and tm+1 are fixed, in
this section we explore objective functions which will be minimized with respect to the remaining
m time points, T = (t1, . . . , tm). We distinguish between selection of optimal sampling time
points for a single subject, with a fixed value of β, versus choosing sampling time points for a
population of β values. In the latter case, we average the single subject objective functions over
an assumed random effect distribution.
Two major techniques for defining the objective functions have been discussed in the liter-
ature. The first uses MSE for estimating AUC while the second uses MSE for estimating the
concentration-time curve using linear interpolation. We summarize three realizations of these
techniques:
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71. Katz and D’Argenio (1983) proposed the following MSE based objective function for esti-
mating AUC:
Obj1(t;β,λ, σ) = E
{
m+1∑
j=1
∫ tj
tj−1
[
fˆj(t)− f(t;β)
]
dt
}2
= [Bias]21 + [Var]1
=
{
E
(
Aˆ
tm+1
t0
)
− Atm+1t0
}2
+
1
4
{
σ20(t1 − t0)2 +
m∑
j=1
σ2j (tj+1 − tj−1)2 + σ2m+1(tm+1 − tm)2
}
, (4)
where E
(
Aˆ
tm+1
t0
)
= 1
2
∑m+1
j=1 (f(tj;β) + f(tj−1;β)) (tj − tj−1).
2. Wang (2001) proposed the following MSE based objective function for estimating the
concentration-time curve using linear interpolation:
Obj2(t;β,λ, σ) =
m+1∑
j=1
∫ tj
tj−1
E
{
fˆj(t)− f(t;β)
}2
dt
= [Bias]22 + [Var]2
=
m+1∑
j=1
∫ tj
tj−1
{
E[fˆj(t)]− f(t;β)
}2
dt+
1
3
m+1∑
j=1
(tj − tj−1)(σ2j−1 + σ2j ), (5)
where E[fˆj(t)] = E[aj]+E[bj]t so that E[aj] = −f(tj ;β)tj−1−f(tj−1;β)tjtj−tj−1 , E[bj] =
f(tj ;β)−f(tj−1;β)
tj−tj−1 .
This objective function is the objective function for the fixed effects model in Kong and
Gonin (2000), assuming no random error.
3. Another way of defining an objective function is to approximate AUC piece-wise and to
base the objective function on the sum of the piece-wise MSEs:
Obj3(t;β,λ, σ) =
m+1∑
j=1
E
{∫ tj
tj−1
[
fˆj(t)− f(t;β)
]
dt
}2
= [Bias]23 + [Var]3
=
m+1∑
j=1
{
E
(
Aˆ
tj
tj−1
)
− Atjtj−1
}2
+
1
4
m+1∑
j=1
(tj − tj−1)2 (σ2j−1 + σ2j ), (6)
where E
(
Aˆ
tj
tj−1
)
= 1
2
(f(tj;β) + f(tj−1;β)) (tj − tj−1).
Several authors (Katz and D’Argenio, 1983; Katz, 1984; Bailer and Piegorsch, 1990; Wang,
2001) have noticed that the variance term tends to dominate the MSE. As a result, these objective
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8functions often do not give intuitively reasonable solutions, even when the measurement error
is relatively small. Figures 2 and 3 demonstrate this by plotting the optimal sampling time
points associated with the various objective functions assuming true parameter values that will
be discussed in Section 5. Notice that the optimal sampling time points tend to be far more
spread out than conventional wisdom would suggest for graphs E and F while the points appear
almost randomly in graphs A-D. We use these results to motivate the practice of focussing on
bias rather than mean squared error to define the objective function.
A second argument to support this conclusion lies in the fact that uncertainty due to the
between-subject variability of PK parameters is usually much greater than the measurement error
(the within-subject variability), even when the suggested PK model reasonably well describes
the concentration profile. Thus, it seems to be more appropriate to use only the bias term as
an objective function, while still accounting for the between-subjects variability. Therefore, we
reexpress the previous objective functions using the bias terms only. We denote the new objective
functions by ObjB1(t;β) = [Bias]
2
1, ObjB2(t;β) = [Bias]
2
2 and ObjB3(t;β) = [Bias]
2
3.
3.1 The grid-wise evaluated objective function
Unfortunately, using the bias only can produce problems where the optimal design requires placing
time points far apart where over and underestimates of the area under the concentration-time
curve cancel out. Figure 4 illustrates an instance of this by plotting the optimal sampling time
points under objective function ObjB1(t;β) (again the true parameter values will be discussed
in Section 5). In practice we have found the same flaw occurs with the objective function
ObjB3(t;β). Among three objective functions, ObjB2(t;β) appears to be resistant to this prob-
lem. However, ObjB2(t;β) requires an explicit integration to construct the function, which is
both difficult and error-prone if the assumed underlying model is complicated.
We propose an objective function which does not require integration yet does not suffer from
the cancelling out problem described above. The basic idea is that each time interval between
tj−1 and tj is divided equally with the number of divisions determined by the length of the interval.
The error between the true AUC and the approximated AUC is then evaluated within each division
and the results are summed up. An example of creating the grid and evaluating the error in a
time interval is shown in Figure 4. More formally, we define the objective function as:
Obj4(t;β) =
m+1∑
j=1
{[
E
(
Aˆ
g(j−1)(1)
tj−1
)− Ag(j−1)(1)tj−1 ]2 + nj∑
k=2
[
E
(
Aˆ
g(j−1)(k)
g(j−1)(k−1)
)− Ag(j−1)(k)g(j−1)(k−1)]2
+
[
E
(
Aˆtjg(j−1)(nj)
)− Atjg(j−1)(nj)]2
}
, (7)
where nj is the number of grids within the interval (tj−1, tj) and g(j−1)(l) = g(j−1)(l)(tj−1, tj)
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9which is a function of tj−1 and tj, and
E
(
Aˆ
g(j−1)(1)
tj−1
)
=
1
2
(
f(tj−1;β) + E[fˆj(g(j−1)(1))]
)(
g(j−1)(1) − tj−1
)
E
(
Aˆ
g(j−1)(k)
g(j−1)(k−1)
)
=
1
2
(
E[fˆj(g(j−1)(k−1))] + E[fˆj(g(j−1)(k))]
)(
g(j−1)(k) − g(j−1)(k−1)
)
E
(
Aˆtjg(j−1)(nj)
)
=
1
2
(
E[fˆj(g(j−1)(nj))] + f(tj;β)
)(
tj − g(j−1)(nj)
)
.
To illustrate Obj4(t;β), suppose that the underestimated area and the overestimated area in
Figure 4 are same. Then the evaluated overall error within the interval tj−1 and tj would be 0 if
the objective function ObjB1(t;β) or ObjB3(t;β) is used whereas the evaluated error would be
the underestimated area plus the overestimated area (whole shaded area) if Obj4(t;β) is used.
While conceivably, the same cancelling out error can occur within a grid of Obj4(t;β), the grid
length can always be decreased until stable estimates are obtained.
3.2 A population-averaged objective function
We define ObjPAr (t;µ, ξ) as the population-averaged objective function corresponding to the
individual objective function ObjBr(t;β) where r = 1, . . . , 4. We define Obj
PA
r (t;µ, ξ) as:
ObjPAr (t;µ, ξ) =
∫
β
ObjBr(t;β) pβ(β) dβ, (8)
where pβ(β) is the joint density function of random effects.
Most of PK models and corresponding objective functions are nonlinear function of parameters;
hence there is no analytical form of ObjPAr (t;µ, ξ) and numerical integration is employed. Usual
numerical integration methods are often technically difficult to be applied in this context. We
therefore use a Monte Carlo integration scheme within our simulated annealing algorithm when
using population averaged objective functions.
4 Optimization Using a Simulated Annealing Algorithm
The simulated annealing algorithm (SA) is a stochastic global optimization method. Simulated
annealing gets its name as it is a conceptual analogue of the cooling (annealing) of high energy
state molten metals in thermodynamics. The annealed metal reaches the global minimum energy
state if the annealing process is very slow, since random fluctuation of the energy of the metal
allows it to escape from local minima. If the metal is cooled quickly, it might not escape from a
local minimum of energy. Like the physical annealing process, the simulated annealing algorithm
allows the current state to move uphill out of a local minimum with some acceptance probability.
This idea was first described in a seminal paper by Metropolis et al. (1953). The acceptance
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probability in SA is controlled by a parameter called the “temperature” which gets its name from
the cooling temperature schedule in the physical annealing process. The readers can find excellent
reviews of SA in Bohachevsky et al. (1986) and Goffe et al. (1994).
Unlike most deterministic algorithms, since SA moves both downhill and uphill along the
surface of the objective function, it theoretically converges to the global minimum for complicated
functions for which derivatives do not exist, have many local minima or high dimensional discrete
or continuous functions. In many cases, if run in a sensible manner, the solution from SA is
insensitive to starting values, which is a major problem for many optimization algorithms. The
algorithm can easily employ a variety of constraints and the implementation is relatively simple
since SA does not require derivatives of the objective function. However, SA is not without its
disadvantages which can include long run times and quite a bit tinkering with the cooling schedule
to obtain a reasonable algorithm.
We adopted SA for the following reasons. First, our objective function is complicated, non-
linear, multimodal and involves many parameters (sampling times). Secondly, SA can easily
incorporate constraints such as discretizing the sampling times or modifying the grid-lengths in
the objective function ObjPA4 (t;µ, ξ). Finally, the use of Monte Carlo integration to estimate
the population-averaged optimal sampling time points using objective function, ObjPA4 (t;µ, ξ),
fits well within the SA framework.
The description of our SA algorithm is as follows while a schematic of the algorithm is shown
in Figure 5. We assume the “true” PK parameters are fixed and known as well as the first and
last sampling times (to be used in the objective function). We initialize the temperature, T (1),
and starting sampling time points t(1) = (t
(1)
0 , . . . , t
(1)
m+1). Then each iteration l = 2, . . . , L is as
follows:
1. set T (l) = T (1)/log(l);
2. randomly choose k uniformly from 1, . . . ,m;
3. simulate tnew uniformly in the interval (t
(l−1)
k−1 , t
(l−1)
k+1 );
4. set t(l) = (t
(l−1)
0 , . . . , t
(l−1)
k−1 , tnew, t
(l−1)
k+1 , . . . , t
(l−1)
m+1 );
5. simulate I random effects vectors, {βi}Ii=1, each from {µ,D(ξ)} for i = 1, . . . , I;
6. calculate φl =
∑
iObj4(t
(l);βi)/I;
7. set p = min{exp(− ∆φ
T (l)
)
, 1} where ∆φ = φl − φl−1;
8. generate u ∼ U [0, 1];
9. accept the current sampling times t(l) if u ≤ p; otherwise t(l) = t(l−1).
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Model ka k V D µk ξk
Fixed effects model 1 (FM1) 0.2 0.1 40 400
Fixed effects model 2 (FM2) 0.8 0.2 40 400
Random effects model 1 (RM1) 0.2 40 400 0.1 0.05
Table 1: The parameters for the examples, where µk and ξk are mean and standard deviation of the
random effect k. These parameters were adopted from Kong and Gonin (2000) for comparison.
For a fixed effects model, we omit Step 5 and replace Step 6 with φl = Obj4(t
(l);β). A benefit
of the algorithm is that timing constraints, such as no two sampling points being too close, can
be easily incorporated into Step 3.
5 Examples
For illustration, consider a pharmacokinetic system of the one-compartment open model with
first-order absorption and first-order elimination kinetics (Gibaldi and Perrier, 1982). That is, the
concentration time curve is parametrized as:
f(t;β) =
kaFD
V (ka − k)(e
−kt − e−kat),
where
β : β= [β1, β2, β3] = [V, ka, k]
F : the fraction of the administered dose D that is absorbed
(assume F = 1 in the examples)
V : the volume of distribution (a proportionality constant relating
the amount of drug to the concentration of drug in the blood)
ka : the apparent first-order absorption rate constant
k : the apparent first-order elimination rate constant.
We focus our discussion on fixed effects models for two sets of PK parameters and a random
effects model where k is random; Table 1 gives the specific parameters values used. The two sets
of fixed effect parameters represent two extremes of the concentration-time curve. In FM1, the
curve is smoothly rising and decaying while in FM2 the curve changes very rapidly.
The optimal sampling times for fixed effects models are shown in Figures 6 and 7. The left
panel shows the (estimated) optimal sampling times obtained using Obj4(t;β) as the objective
function while the right panel shows the optimal sampling times obtained using ObjB2(t;β)
both estimated by SA. The resulting sampling schedules for the two objective functions are very
similar regardless of m. Furthermore, the optimal sampling times obtained using ObjB2(t;β)
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under SA are similar to those obtained by Kong and Gonin (2000) who used the same objective
function (using a different algorithm). Of course when the concentration-time curve is smooth,
such as under model FM1, the number of sampling time points can be reduced (see Figure 6).
However, we note that care must be taken because estimation of the subject specific k is not
represented in the objective function. With m = 8 an insufficient number of points (only two)
are represented in the tail of the concentration-time curve when the last 3 time points need to
be used to estimate the subject specific k.
For FM2, the optimal sampling time points obtained using Obj4(t;β) are very different from
those obtained using ObjB2(t;β) unless m is large. Since the rate of absorption is very large
compared to the rate of elimination and the rate of elimination is also large for the FM2, the profile
is rising very quickly, has a sharp peak, then decreases very rapidly. The optimization procedure in
this case is almost entirely determined by the objective function, which is unfortunate because the
two functions are conceptually similar. Furthermore, stable convergence was difficult to obtain
because of the many local minima of similar magnitude to the global minimum. Thus, it is
probably more feasible to transfer the problem to a scale that is less dependent on the objective
function.
We focus our attention on estimating the bulk of the area under the concentration-time
curve, say for a time interval [0, tmax + w] for some w. Then, we suggest that users employ
the logarithmic trapezoidal method (Yeh and Kwan, 1978; Chiou, 1978) for estimating AUC.
Technically, this focus is justified because when using this method, only the (fixed) final time
point after tmax + w is required if the PK model is correct and the observations are measured
without error. Of course, several points should be used in practice because the PK model is never
exactly correct and measurement error is always present.
Focussing on this interval, we find that the results are more robust to specification of the
objective function and converged more quickly. Since tmax varies across subjects, it is necessary
to take w to be large enough in order for the time interval [0, tmax + w] to be able to cover the
peak. Figure 8 shows the sampling time points using this approach for w = 3.7. The left panel
shows the log of the concentration time profile while the right shows the curve on the raw scale.
To obtain population-averaged optimal sampling time points, we need to assume a distribution
for the PK parameters. For model RM1, we assume that k follows a lognormal distribution
with mean µk = 0.1 and standard deviation ξk = 0.05 (similar to Kong and Gonin, 2000).
Further, we assume that ka > k (also as in Kong and Gonin, 2000), which is reasonable for most
oral conventional/immediate release drug products. We emphasize that our objective function,
ObjPA4 (t;µ, ξ), does not require this assumption.
The obtained optimal sampling time points are shown in Figure 9. It is interesting to note
that the optimal sampling time points for the random effects model are quite different from those
for the fixed effects model. It is also interesting to note that the sampling time points for the
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random effects model have been shifted, resulting in one less point in the absorption phase and
one more point in the elimination phase of the concentration-time curve. The additional point in
the elimination phase seems to be needed to account for variability due to the random elimination
rate constant, k. The optimal sampling time points for the random effects model of Kong and
Gonin (2000) are slightly different from our result, which might be due to the different method
of numerical integration.
Before concluding this section we note that a strength of the SA approach is that a model with
multidimensional random effects could be implemented using our approach with little additional
effort.
6 Summary and Discussion
In this manuscript, we emphasized that the within-subject variance term of objective functions
based on MSE over-dominated the selection of sampling time points. In addition, since the
between-subject variability in PK parameters is usually much greater than the within-subject
variability, it is more important to take into account the between-subject variability. Thus, we
recommend to use an objective function based on the squared bias as an exploratory procedure
to get a general idea about the shape of profile. Then we suggest using a population-averaged
objective function to design the sampling schedule.
We proposed a grid-wise evaluated objective function which can overcome some of the disad-
vantages of other objective functions in the literature. The proposed objective function is simple
to implement and produced reasonable sampling time points consistent with those produced by
the objective function of Kong and Gonin (2000). Because the newly developed objective function
is not amenable to most non-linear optimization methods, we implemented a simulated annealing
algorithm. Furthermore, for obtaining population-averaged results, we embedded Monte Carlo
numerical integration within the algorithm. An appealing aspect of SA is the ease of handling
the Monte Carlo integration and stochastic optimization within a unified framework. Also, the
simulated annealing algorithm easily handles constraints on the sampling times.
As shown in the examples, when the profile is smooth, both the grid-wise evaluated objective
function and ObjB2(t;β) gave similar results. However, when the profile is sharp, special attention
is needed and one should not use any optimization method blindly. We suggested a strategy to
select time points to estimate the bulk of the area under the concentration-time curve. However,
it would seem that prior knowledge regarding subjects is important to select time points in these
scenarios.
It should be noted in BE studies, Cmax and tmax are also important in addition to AUC. A
concern when estimating these parameters is that sampling times may straddle the functional
maximum. We note that the error in the AUC approximation is directly related to the curvature
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of the concentration-time curve. (This is seen most clearly with Wang (2001)’s approximated
objective function which formally depends on the second derivative.) As a result, in many case
both the grid-wise objective function, ObjB2(t;β) and their population-averaged counterparts
used for estimating AUC concentrated points around tmax (see Figure 6-9). Encouragingly, these
objective functions produced reasonable sampling time points for estimating Cmax and tmax.
Broadly speaking, the optimal sampling time points change drastically depending on the
underlying model. Thus, if the number of sampling times is limited for either clinical or economic
reasons, it is important to understand the optimal placement of the sampling times given various
underlying models. The objective function and stochastic optimization method presented in this
manuscript would be useful tools to aid in the discussion of PK study design.
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Figure 1: The estimated AUC, Cmax and tmax using conventional sampling time points. The
dotted line and solid line present the true underlying concentration-time curve and the linear
interpolation of sampling time points assuming no random errors, respectively. The estimated
AUC via the trapezoidal approximation is the shaded area under the solid line.
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(A) Obj1(t;β,λ, σ), σ = 0.1 (B) Obj1(t;β,λ, σ), σ = 0.3
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(C) Obj2(t;β,λ, σ), σ = 0.1 (D) Obj2(t;β,λ, σ), σ = 0.3
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(E) Obj3(t;β,λ, σ), σ = 0.1 (F ) Obj3(t;β,λ, σ), σ = 0.3
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Figure 2: The estimated sampling time points using the mean squared error objective functions
for fixed effects model with parameters ka = 0.2, k = 0.1, V = 40, Dose = 400, λ1 = 0, λ2 = 2
(the model is discussed in Section 5). The dotted line and solid line present the true underlying
concentration-time curve and the linear interpolation of optimal sampling time points, respectively.
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(A) Obj1(t;β,λ, σ), σ = 0.1 (B) Obj1(t;β,λ, σ), σ = 0.3
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(C) Obj2(t;β,λ, σ), σ = 0.1 (D) Obj2(t;β,λ, σ), σ = 0.3
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(E) Obj3(t;β,λ, σ), σ = 0.1 (F ) Obj3(t;β,λ, σ), σ = 0.3
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Figure 3: The estimated sampling time points using the mean squared error based objective
functions for fixed effects model with parameters ka = 0.8, k = 0.2, V = 40, Dose = 400, λ1 =
0, λ2 = 2 (the model is discussed in Section 5). The dotted line and solid line present the true
underlying concentration-time curve and the linear interpolation of optimal sampling time points,
respectively.
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Figure 4: The demonstration of the grid-wise evaluated objective function to prevent overesti-
mated and underestimated errors from being cancelled out. The dotted line and solid line present
the true underlying concentration-time curve with parameters ka = 0.2, k = 0.1, V = 40, Dose =
400, λ1 = 0, λ2 = 2 (the model is discussed in Section 5) and the linear interpolation of optimal
sampling time points under objective function ObjB1(t;β), respectively.
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Figure 5: A demonstration of the simulated annealing algorithm from Section 4.
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Figure 6: The optimal sampling time points for fixed effects model (FM1) with parameters
ka = 0.2, k = 0.1, V = 40, Dose = 400. The plots on the left are obtained using the grid-wise
evaluated objective function Obj4(t;β) while the plots on the right are obtained using ObjB2(t;β)
implemented by SA. The dotted line and solid line present the true underlying concentration-time
curve and the linear interpolation of optimal sampling time points, respectively.
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Figure 7: The optimal sampling time points for fixed effects model (FM2) with parameters
ka = 0.8, k = 0.2, V = 40, Dose = 400. The plots on the left are the optimal sampling time
points using the grid-wise evaluated objective function Obj4(t;β) while the plots on the right are
the optimal sampling time points using ObjB2(t;β) implemented by SA. The dotted line and solid
line present the true underlying concentration-time curve and the linear interpolation of optimal
sampling times, respectively.
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Figure 8: The optimal sampling time points for fixed effects model (FM2) with parameters
ka = 0.8, k = 0.2, V = 40, Dose = 400 using our proposed strategy. The left panel shows the
log of the concentration vs. time and the right panel shows the concentration vs. time.
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Figure 9: The comparison of the optimal sampling time points for fixed effects model (FM1) (top
panel) and for random effects model (RM1) (bottom panel) where FM1 has parameters ka =
0.2, k = 0.1, V = 40, Dose = 400 and RM1 has fixed parameters ka = 0.2, V = 40, Dose = 400
and random effect k with the mean µk = 0.1 and standard deviation ξk = 0.05 where ka > k.
The plots on the left are the optimal sampling time points using the grid-wise evaluated function
implemented by SA while the plots on the right are the optimal sampling time points from Kong
and Gonin (2000).
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